Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FS222 |
| Synonyms | |
| Therapy Description |
FS222 is a tetravalent bispecific antibody that binds to PD-L1 (CD274) and CD137 (4-1BB), which crosslinks cytotoxic T-lymphocytes to PD-L1-expressing tumor cells, potentially resulting in CD137 mediated activation of T-cells (PMID: 32345647). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FS222 | FS-222|FS 222 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 133 TNFRSF9 Antibody 36 | FS222 is a tetravalent bispecific antibody that binds to PD-L1 (CD274) and CD137 (4-1BB), which crosslinks cytotoxic T-lymphocytes to PD-L1-expressing tumor cells, potentially resulting in CD137 mediated activation of T-cells (PMID: 32345647). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04740424 | Phase I | FS222 | FS222 First in Human Study in Patients With Advanced Malignancies | Recruiting | ROU | POL | NLD | ESP | DEU | AUS | 1 |